» Articles » PMID: 20625533

High-Density Lipoprotein Proteomics: Identifying New Drug Targets and Biomarkers by Understanding Functionality

Overview
Publisher Springer
Date 2010 Jul 14
PMID 20625533
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Recent proteomics studies on human plasma high-density lipoprotein (HDL) have discovered up to 50 individual protein constituents. Many of these have known functions that vary surprisingly from the lipid transport roles commonly thought to mediate HDL's ability to protect from coronary artery disease. Given newly discovered roles in inflammation, protease inhibition, complement regulation, and innate immunity, many have begun to view HDL as a broad collection of distinct particle subfamilies, each distinguished by unique protein compositions and functions. Herein we review recent applications of high-resolution proteomics to HDL and summarize evidence supporting the idea of HDL functional subspeciation. These studies have set the stage for a more complete understanding of the molecular basis of HDL functional heterogeneity and hold promise for the identification of new biomarkers that can predict disease or evaluate the success of clinical interventions.

Citing Articles

High-Density Lipoprotein Cholesterol: A Component of the Metabolic Syndrome with a New Role in Lung Function.

Wang F, Tian D, Zhao Y, Li J, Chen X, Zhang Y Evid Based Complement Alternat Med. 2021; 2021:6615595.

PMID: 34188689 PMC: 8192195. DOI: 10.1155/2021/6615595.


A dual apolipoprotein C-II mimetic-apolipoprotein C-III antagonist peptide lowers plasma triglycerides.

Wolska A, Lo L, Sviridov D, Pourmousa M, Pryor M, Ghosh S Sci Transl Med. 2020; 12(528).

PMID: 31996466 PMC: 8359806. DOI: 10.1126/scitranslmed.aaw7905.


High-density lipoprotein reduces inflammation from cholesterol crystals by inhibiting inflammasome activation.

Thacker S, Zarzour A, Chen Y, Alcicek M, Freeman L, Sviridov D Immunology. 2016; 149(3):306-319.

PMID: 27329564 PMC: 5046053. DOI: 10.1111/imm.12638.


HDL particle number and size as predictors of cardiovascular disease.

Kontush A Front Pharmacol. 2015; 6:218.

PMID: 26500551 PMC: 4593254. DOI: 10.3389/fphar.2015.00218.


A Comparison of Methods To Enhance Protein Detection of Lipoproteins by Mass Spectrometry.

Heink A, Davidson W, Swertfeger D, Lu L, Shah A J Proteome Res. 2015; 14(7):2943-50.

PMID: 26039899 PMC: 4714602. DOI: 10.1021/acs.jproteome.5b00270.


References
1.
Shiflett A, Bishop J, Pahwa A, Hajduk S . Human high density lipoproteins are platforms for the assembly of multi-component innate immune complexes. J Biol Chem. 2005; 280(38):32578-85. DOI: 10.1074/jbc.M503510200. View

2.
Asztalos B, Schaefer E . High-density lipoprotein subpopulations in pathologic conditions. Am J Cardiol. 2003; 91(7A):12E-17E. DOI: 10.1016/s0002-9149(02)03383-0. View

3.
Heinecke J . The HDL proteome: a marker--and perhaps mediator--of coronary artery disease. J Lipid Res. 2008; 50 Suppl:S167-71. PMC: 2674735. DOI: 10.1194/jlr.R800097-JLR200. View

4.
Jonas A . Lecithin-cholesterol acyltransferase in the metabolism of high-density lipoproteins. Biochim Biophys Acta. 1991; 1084(3):205-20. DOI: 10.1016/0005-2760(91)90062-m. View

5.
Canas B, Lopez-Ferrer D, Ramos-Fernandez A, Camafeita E, Calvo E . Mass spectrometry technologies for proteomics. Brief Funct Genomic Proteomic. 2007; 4(4):295-320. DOI: 10.1093/bfgp/eli002. View